| scholarly article | Q13442814 |
| P50 | author | Giovanni Martinelli | Q66370881 |
| P2093 | author name string | Fedro Peccatori | |
| Maurizio Civelli | |||
| Alessandro Colombo | |||
| Carlo M Cipolla | |||
| Daniela Cardinale | |||
| Giuseppina Lamantia | |||
| Maria T Sandri | |||
| Nicola Colombo | |||
| Cesare Fiorentini | |||
| Marina Boeri | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 2749-2754 | |
| P577 | publication date | 2004-05-17 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy | |
| P478 | volume | 109 |
| Q39157770 | 123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy |
| Q57057499 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines |
| Q46350339 | A case of cardiogenic shock caused by capecitabine treatment |
| Q35232931 | A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer |
| Q37197579 | A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer |
| Q90178683 | A quality improvement approach to reducing hospital readmissions in patients with cancer and heart failure |
| Q37052852 | A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology |
| Q52650702 | Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. |
| Q87205182 | Adding insult to injury: heart failure and incident cancer |
| Q38357704 | Advanced heart failure due to cancer therapy |
| Q90777008 | Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia |
| Q38747992 | Alternative Biomarkers for Combined Biology |
| Q42706225 | An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity |
| Q37694541 | Anthracycline Chemotherapy and Cardiotoxicity. |
| Q58803993 | Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease |
| Q34477415 | Anthracycline cardiotoxicity: from bench to bedside |
| Q34639876 | Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment |
| Q33658456 | Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care |
| Q38727423 | Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker? |
| Q38542462 | Anthracycline-Induced Cardiomyopathy in Adults |
| Q34626238 | Anthracycline-associated cardiotoxicity in survivors of childhood cancer |
| Q38205702 | Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment |
| Q51319986 | Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. |
| Q36846891 | Anthracycline-induced chronic cardiotoxicity and heart failure |
| Q89876415 | Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper |
| Q33896047 | Assessment of cardiotoxicity with cardiac biomarkers in cancer patients |
| Q37129069 | Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial |
| Q36988278 | Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab |
| Q99569915 | Association between history of cancer and major adverse cardiovascular events in patients with chest pain presenting to the emergency department: a secondary analysis of a prospective cohort study |
| Q28080002 | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| Q36939536 | Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance |
| Q94336593 | Author`s Reply |
| Q92120577 | BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis |
| Q95942184 | Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European So |
| Q38015746 | Biological drugs: classic adverse effects and new clinical evidences |
| Q88868148 | Biomarker Discovery in Cardio-Oncology |
| Q37207351 | Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. |
| Q46328753 | Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children |
| Q61454620 | Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity |
| Q28087152 | Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations |
| Q47703138 | Biomarkers in cancer therapy related cardiac dysfunction (CTRCD). |
| Q38362383 | Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity |
| Q48413982 | Can cardio-oncology deliver better care internationally? |
| Q48495062 | Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation? |
| Q36451899 | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging |
| Q92433295 | Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician |
| Q88711817 | Cancer and Heart Failure: Understanding the Intersection |
| Q38025824 | Cancer drugs and the heart: importance and management |
| Q30500830 | Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. |
| Q42547157 | Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities |
| Q88711811 | Cardiac Atrophy and Heart Failure In Cancer |
| Q38632789 | Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity |
| Q57111760 | Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This? |
| Q92408562 | Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs |
| Q89759750 | Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis |
| Q48457118 | Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines |
| Q51739297 | Cardiac complications of chemotherapy: role of biomarkers. |
| Q35039549 | Cardiac dysfunction after cancer treatment |
| Q48466932 | Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation |
| Q28081385 | Cardiac risk in the treatment of breast cancer: assessment and management |
| Q26851957 | Cardiac toxicity in cancer survivors |
| Q38091377 | Cardiac toxicity of anticancer agents |
| Q35949084 | Cardiac toxicity of high-dose chemotherapy |
| Q42513963 | Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation |
| Q92776906 | Cardio-Oncology at the Beginning of a New Decade |
| Q39076609 | Cardio-oncology |
| Q38416816 | Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity |
| Q39303131 | Cardio-oncology in the older adult. |
| Q37823884 | Cardio-oncology/onco-cardiology. |
| Q26750878 | Cardio-oncology: Concepts and practice |
| Q38657849 | Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts |
| Q53292554 | Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. |
| Q90729130 | Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology |
| Q30471284 | Cardio-oncology: a new medical issue |
| Q38551766 | Cardio-oncology: an ongoing evolution. |
| Q38665281 | Cardio-oncology: cardiovascular complications of cancer therapy |
| Q57108766 | Cardio-oncology: protecting the heart from curative breast cancer treatment |
| Q33701308 | Cardio-oncology: what you need to know now for clinical practice and echocardiography |
| Q38904284 | Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention? |
| Q38242641 | Cardiomyopathy associated with cancer therapy |
| Q38591768 | Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis |
| Q36710842 | Cardiorespiratory fitness in breast cancer survivors |
| Q48008904 | Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? |
| Q43807501 | Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers |
| Q37663263 | Cardiotoxicity Following Cancer Treatment |
| Q42373758 | Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. |
| Q90178707 | Cardiotoxicity after cancer treatment: a process map of the patient treatment journey |
| Q39270177 | Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant. |
| Q37025960 | Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. |
| Q38508938 | Cardiotoxicity due to Chemotherapy: the Role of Biomarkers |
| Q91650757 | Cardiotoxicity of Anthracyclines |
| Q33574045 | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention |
| Q26766063 | Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management |
| Q37788952 | Cardiotoxicity of anticancer treatments: what the cardiologist needs to know |
| Q36676062 | Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy |
| Q38021523 | Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up |
| Q55438414 | Cardiotoxicity of immune checkpoint inhibitors. |
| Q45073135 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. |
| Q52677836 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. |
| Q26864094 | Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level |
| Q34572109 | Cardiovascular effects in childhood cancer survivors treated with anthracyclines |
| Q38338228 | Cardiovascular prevention in the cancer survivor |
| Q101140295 | Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation |
| Q34630349 | Cardiovascular toxicities from systemic breast cancer therapy |
| Q37430831 | Cardiovascular toxicity caused by cancer treatment: strategies for early detection |
| Q37967508 | Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology |
| Q38978062 | Caring for cancer survivors: more than just checking the blood pressure and measuring the ejection fraction |
| Q92776949 | Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction |
| Q35925266 | Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes |
| Q54959206 | Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. |
| Q90415345 | Chemotherapy Related Severe Cardiac Dysfunction - Case Report |
| Q37045339 | Chemotherapy and cardiotoxicity |
| Q35868495 | Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management |
| Q51224671 | Chemotherapy-induced Cardiotoxicity. |
| Q37867085 | Chemotherapy-induced cardiomyopathy |
| Q38580452 | Chemotherapy-induced cardiomyopathy |
| Q34258080 | Chemotherapy-induced cardiotoxicity |
| Q53748861 | Chemotherapy-induced cardiotoxicity: importance of early detection. |
| Q92218673 | Chemotherapy-related Cardiomyopathy |
| Q38231301 | Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship |
| Q94485466 | Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial |
| Q36582822 | Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort |
| Q50135829 | Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. |
| Q38717558 | Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q38559474 | Current and emerging modalities for detection of cardiotoxicity in cardio-oncology |
| Q38845535 | Current views on anthracycline cardiotoxicity. |
| Q90343457 | Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients |
| Q37057941 | Detection and monitoring of cardiotoxicity-what does modern cardiology offer? |
| Q90178736 | Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin |
| Q41098209 | Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience |
| Q53075042 | Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. |
| Q33565936 | Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction |
| Q44849977 | Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. |
| Q37822734 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q39033784 | Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited |
| Q93175092 | Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma |
| Q42706690 | Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion |
| Q36988282 | Early detection and prediction of cardiotoxicity in chemotherapy-treated patients |
| Q37993439 | Early detection of chemotherapy-related left ventricular dysfunction |
| Q34855776 | Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab |
| Q38938410 | Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy |
| Q37671456 | Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy |
| Q36894836 | Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial |
| Q55262271 | Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. |
| Q90178709 | Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group |
| Q47131512 | Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer |
| Q90202998 | Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease |
| Q36902805 | Elevated troponin I and its prognostic significance in acute liver failure |
| Q63170243 | Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? |
| Q40047999 | Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned? |
| Q36774710 | Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study |
| Q51802343 | Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens. |
| Q36836161 | Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. |
| Q48461764 | Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience |
| Q34570840 | Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients |
| Q26785410 | Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors |
| Q30401812 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging |
| Q48922603 | Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. |
| Q45917757 | First annual Canadian Cardiac Oncology Network conference. |
| Q54645696 | Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. |
| Q38842771 | From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. |
| Q41288150 | Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention |
| Q89580190 | Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis |
| Q54535935 | Global longitudinal strain: mature for early detection of anthracyclines-induced cardiotoxicity? |
| Q38559133 | Heart failure and chemotherapeutic agents |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q51498136 | Heart matters: cardiovascular complications related to cancer treatment. |
| Q50948084 | Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats. |
| Q38868285 | High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury |
| Q37977873 | High-sensitive troponin T measurements: what do we gain and what are the challenges? |
| Q42117489 | High-sensitivity cardiac troponin testing for primary care: analytical assay considerations required before widespread implementation |
| Q57453139 | How to build a cardio-oncology service? |
| Q38171887 | How to monitor cardiac toxicity of chemotherapy: time is muscle! |
| Q55409972 | Identifying and managing the adverse effects of immune checkpoint blockade. |
| Q38551772 | Identifying cancer patients at risk for cardiotoxicity |
| Q38197733 | Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction |
| Q38978030 | Improving prediction of cardiovascular complications of cancer therapy: what does the future hold? |
| Q86344610 | Intensified home haemodialysis for managing severe cardiac failure |
| Q80533090 | Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? |
| Q61917199 | Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome? |
| Q40809782 | Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. |
| Q88008688 | Left Ventricular Dysfunction and Chemotherapeutic Agents |
| Q89707927 | Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis |
| Q38982319 | Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool? |
| Q36395125 | Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines |
| Q36339976 | Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab |
| Q37100862 | Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease |
| Q38192517 | Making sense of high sensitivity troponin assays and their role in clinical care |
| Q86805028 | Managing cardiotoxicity of chemotherapy |
| Q35562745 | Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers |
| Q36410651 | Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer |
| Q50678211 | Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin. |
| Q92462147 | Monitoring the heart during cancer therapy |
| Q47098878 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study |
| Q53699470 | New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. |
| Q37514230 | New and emerging biomarkers of heart failure |
| Q39005990 | New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. |
| Q30461444 | Noninvasive diagnosis of chemotherapy related cardiotoxicity |
| Q37426212 | Old and new biomarkers of heart failure. |
| Q47681122 | Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy |
| Q26744675 | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity |
| Q36163330 | Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy |
| Q89993252 | Personalized Approach to Cancer Treatment-Related Cardiomyopathy |
| Q37434061 | Perspective on the clinical application of troponin in heart failure and states of cardiac injury |
| Q35039202 | Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury |
| Q92612178 | Position Statement on Indications of Echocardiography in Adults - 2019 |
| Q94547024 | Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer |
| Q91700909 | Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week |
| Q33386386 | Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q38786052 | Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments |
| Q57113998 | Priorities in the Cardiovascular Care of Breast Cancer Survivors |
| Q42380276 | Prognostic Significance of Troponin Elevation for Long-Term Mortality after Ischemic Stroke |
| Q35122242 | Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure |
| Q34466688 | Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy |
| Q38001376 | Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. |
| Q58693257 | Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers |
| Q59478893 | Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic |
| Q28087776 | Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs |
| Q38237495 | Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway |
| Q52364966 | Redefining biomarkers in heart failure. |
| Q36562008 | Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy. |
| Q36626934 | Roadmap for biomarkers of cancer therapy cardiotoxicity |
| Q55429574 | Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. |
| Q38896955 | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
| Q35716026 | SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly |
| Q35623306 | Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients |
| Q44918082 | Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q38982304 | Should the 'echo guidelines' be followed in cancer patients? |
| Q39962402 | Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. |
| Q48143732 | State of the art review: Chemotherapy-induced cardiotoxicity in children. |
| Q38551776 | Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers |
| Q64233611 | Subclinical Left Ventricular Dysfunction During Chemotherapy |
| Q64103972 | Surviving Cancer without a Broken Heart |
| Q33988329 | Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? |
| Q36245324 | Targeted therapies in breast cancer: are heart and vessels also being targeted? |
| Q87659774 | The Future Role of Cardio-oncologists |
| Q97544688 | The Role of Biomarkers in Cardio-Oncology |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q38728535 | The Role of Biomarkers in Detection of Cardio-toxicity |
| Q92980788 | The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics |
| Q61454606 | The breast cancer patient in the cardioncology unit |
| Q37613422 | The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients |
| Q43958676 | The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study. |
| Q38140759 | The evolving role of cardiac troponin in the evaluation of cardiac disorders |
| Q99609954 | The impact of cardiac troponin in elderly patients in the absence of acute coronary syndrome: A systematic review |
| Q38190105 | The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |
| Q34292469 | The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats |
| Q38148968 | Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity |
| Q37145885 | Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer |
| Q33647686 | Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation |
| Q33840140 | Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population |
| Q54705428 | Trastuzumab-related cardiac events in the treatment of early breast cancer. |
| Q36150546 | Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. |
| Q37071685 | Troponin in hematologic oncology |
| Q34117708 | Troponin: the biomarker of choice for the detection of cardiac injury |
| Q91266299 | Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis |
| Q89184149 | Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity |
| Q38686222 | Update on cardiotoxicity of anti-cancer treatments |
| Q90178674 | Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series |
| Q38503419 | Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q46658938 | Use of wave intensity analysis of carotid arteries in identifying and monitoring left ventricular systolic function dynamics in rabbits |
| Q39018351 | Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy |
| Q38069202 | Using cardiac biomarkers and treating cardiotoxicity in cancer |
| Q51530456 | Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities. |
| Q35588736 | Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy |
| Q49163835 | Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients |
Search more.